News about Global Pharma

Pfizer to Acquire Metsera, Expand Obesity and Cardiometabolic Drug Pipeline

Pfizer is set to acquire Metsera, a clinical-stage biopharmaceutical company focused on developing the next generation of medicines for obesity and cardiometabolic diseases.

Global Pharma | 23/09/2025 | By Dineshwori |  195

Alnylam Pharmaceuticals Joins Alliance for Genomic Discovery to Advance RNAi Therapeutics

Alnylam Pharmaceuticals has become the ninth member of the Alliance for Genomic Discovery (AGD), joining AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, and Novo Nordisk.

Global Pharma | 19/09/2025 | By Dineshwori |  187

Laborate Pharmaceuticals Appoints IPS Veteran Sanjay Kundu as Independent Director

As Independent Director at Laborate Pharmaceuticals, Sanjay Kundu will provide independent oversight, strengthen corporate governance, and promote transparent decision-making.

Global Pharma | 18/09/2025 | By Dineshwori |  386

Aurobindo Pharma Expands Business in Malaysia with New Subsidiary

Aurobindo Pharma has announced the incorporation of a new wholly owned subsidiary, Aurobindo Pharma (Malaysia) SDN. BHD., through its subsidiary Helix Healthcare B.V.

Global Pharma | 18/09/2025 | By Dineshwori |  582

Roche to Acquire 89bio in Deal Worth Up to USD 3.5 Billion

Roche has entered into a merger agreement to acquire 89bio, a San Francisco-based clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and cardiometabolic diseases.

Global Pharma | 18/09/2025 | By Dineshwori |  234

AltrixBio Raises USD 5 Million Series A Financing and Appoints David Pass as CEO

Dr David Pass, a veteran of the pharma, biotech, and medical device sectors with a track record of scaling programs to over USD 1 billion in sales, succeeds AltrixBio Co-Founder and CEO Nancy Briefs, who led the company from inception and will now serve as Executive Chair.

Global Pharma | 18/09/2025 | By Dineshwori |  370

Biocon Biologics Secures US FDA Approval for Denosumab Biosimilars Bosaya and Aukelso

The US Food and Drug Administration (FDA) has approved Biocon Biologics' denosumab biosimilars, Bosaya (denosumab-kyqq) 60 mg/mL injection in a single-dose prefilled syringe (PFS) and Aukelso (denosumab-kyqq) 120 mg/1.7 mL (70 mg/mL) injection in a single-dose vial, biosimilars of Prolia and Xgeva, respectively.

Global Pharma | 17/09/2025 | By Dineshwori |  479

GAIASO Theranostics Appoints Dr. Tracey Brown as New CEO

GAIASO Theranostics, an Australia-based biotech company pioneering next-generation precision radiopharmaceuticals for women’s cancers, has appointed Dr. Tracey Brown as its new Chief Executive Officer (CEO).

Global Pharma | 17/09/2025 | By Dineshwori |  391

Lupin Secures US FDA Approval for Lenalidomide Capsules

The approved Lenalidomide Capsules, bioequivalent to Revlimid by Bristol-Myers Squibb, will be produced at Lupin’s Pithampur site in India.

Global Pharma | 17/09/2025 | By Dineshwori |  336

Lilly to Establish USD 5 Billion API Manufacturing Facility in Virginia

The new site in Virginia marks the first of four new US manufacturing sites that Lilly plans to announce this year.

Global Pharma | 17/09/2025 | By Dineshwori |  198